Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? (Q36591722)

15 August 2017

1 reference

title

Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? (English)

1 reference

15 August 2017

0 references

Julien Becker

1

1 reference

15 August 2017

Carine Delayre-Orthez

series ordinal

2

1 reference

15 August 2017

Nelly Frossard

series ordinal

3

1 reference

15 August 2017

Françoise Pons

series ordinal

4

1 reference

15 August 2017

1 October 2006

1 reference

Fundamental and Clinical Pharmacology

15 August 2017

1 reference

15 August 2017

20

1 reference

15 August 2017

5

1 reference

15 August 2017

429-447

1 reference

Peroxisome proliferator-activated receptors: nuclear control of metabolism

15 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor/retinoid X receptor heterodimers in the absence and presence of ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

The PPARalpha-leukotriene B4 pathway to inflammation control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Prostacyclin-dependent apoptosis mediated by PPAR delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

The regulation of uncoupling protein-2 gene expression by omega-6 polyunsaturated fatty acids in human skeletal muscle cells involves multiple pathways, including the nuclear receptor peroxisome proliferator-activated receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Differential activation of peroxisome proliferator-activated receptors by eicosanoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Roles of PPARs in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

An overview on biological mechanisms of PPARs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor alpha target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptors beta/delta: emerging roles for a previously neglected third family member

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

The role of PPARs in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

PPAR agonists in the treatment of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Role of PPARgamma in macrophage biology and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptors as new molecular targets in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Expression of PPARgamma in eosinophils and its functional role in survival and chemotaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

PPAR‐α and ‐γ but not ‐δ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF‐κB‐independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor gamma regulates eosinophil functions: a new therapeutic target for allergic airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

The mouse CCR2 gene is regulated by two promoters that are responsive to plasma cholesterol and peroxisome proliferator-activated receptor gamma ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

WY 14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

PPARalpha activation abolishes LDL-stimulated IL-8 production via AP-1 deactivation in human aortic smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptors in inflammation control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Inhibition of cytokine-induced matrix metalloproteinase 9 expression by peroxisome proliferator-activated receptor alpha agonists is indirect and due to a NO-mediated reduction of mRNA stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Fenofibrate, a peroxisome proliferator-activated receptor alpha activator, suppresses experimental autoimmune myocarditis by stimulating the interleukin-10 pathway in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Expression of cytochrome P450 4A mRNA in mouse lung: effect of clofibrate and interleukin-1beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Inhibition of Interleukin-4 Production in CD4+T Cells by Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Ligands: Involvement of Physical Association between PPAR-γ and the Nuclear Factor of Activated T Cells Transcription Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Transcription factors and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

15-Deoxy-delta(12,14)-prostaglandin J2 inhibits the IL-1beta-induced expression of granulocyte-macrophage colony-stimulating factor in BEAS-2B bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Antiinflammatory Roles of Peroxisome Proliferator–activated Receptor γ in Human Alveolar Macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor-gamma ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor-gamma expression in lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Expression Is Decreased in Pulmonary Hypertension and Affects Endothelial Cell Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Nrf2, a multi-organ protector?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Expression of the Peroxisome Proliferator-activated Receptor Gene Is Stimulated by Stress and Follows a Diurnal Rhythm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Inhibition of monocyte chemoattractant protein-1 expression in cytokine-treated human lung epithelial cells by thiazolidinedione

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

PPAR gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptors and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

PPAR-gamma agonists as therapy for diseases involving airway neutrophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor γ ligands attenuate immunological symptoms of experimental allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor gamma inhibits the migration of dendritic cells: consequences for the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

PPARgamma antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

ROLE OF ENDOGENOUS AND EXOGENOUS LIGANDS FOR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR alpha IN THE DEVELOPMENT OF BLEOMYCIN-INDUCED LUNG INJURY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Hepatic expression of PPARα, a molecular target of fibrates, is regulated during inflammation in a gender-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

Rat PPARs: Quantitative Analysis in Adult Rat Tissues and Regulation in Fasting and Refeeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00425.X

10.1111/J.1472-8206.2006.00425.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference